Adaptimmune Therapeutics plc Stock price
Equities
ADAP
US00653A1079
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -0.68% | -4.55% | +85.37% |
Financials (USD)
Sales 2024 * | 81.85M | Sales 2025 * | 73.92M | Capitalization | 363M |
---|---|---|---|---|---|
Net income 2024 * | -96M | Net income 2025 * | -120M | EV / Sales 2024 * | 4.43 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.91 x |
P/E ratio 2024 * |
-12.3
x | P/E ratio 2025 * |
-6.39
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.06% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | -0.68% | ||
1 week | -4.55% | ||
Current month | -6.37% | ||
1 month | +22.50% | ||
3 months | +227.03% | ||
6 months | +98.51% | ||
Current year | +85.37% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 1.47 | -0.68% | 1,093,143 |
24-03-15 | 1.48 | +1.37% | 634,191 |
24-03-14 | 1.46 | -8.18% | 1,339,697 |
24-03-13 | 1.59 | +6.71% | 1,398,467 |
24-03-12 | 1.49 | -3.25% | 1,624,048 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+85.37% | 363M | |
+1.10% | 106B | |
+9.29% | 103B | |
-3.00% | 21.44B | |
-11.89% | 22.11B | |
-26.59% | 20.99B | |
-5.20% | 19.44B | |
-6.58% | 17.6B | |
+5.83% | 13.88B | |
+7.46% | 11.75B |